Abstract
Our findings indicate that both genes might play a role in the chronification of depression and NR3C1 may be relevant for ECT response prediction.
Introduction
Major Depressive Disorder (MDD) remains a significant global health challenge, characterized by high rates of treatment resistance. Electroconvulsive Therapy (ECT) is a primary intervention for severe MDD, yet its efficacy varies, with remission rates often falling below 50%. This study investigates the role of the Hypothalamic-Pituitary-Adrenal (HPA) axis—the body's central stress-response system—in MDD pathology and treatment response. Specifically, we examined DNA methylation patterns of the glucocorticoid receptor (NR3C1) and proopiomelanocortin (POMC) genes as potential biomarkers for disease severity and ECT outcome.
Methods
The study utilized blood samples from the Northern German Electroconvulsive Therapy Outcome Registry (NEKTOR). Participants were categorized into three groups: patients with severe MDD undergoing ECT (n=31), unmedicated depressed controls (UDC; n=19), and healthy controls (HC; n=20). DNA methylation was assessed using bisulfite sequencing and Sanger sequencing across 41 sites in NR3C1 and 17 sites in POMC. Mixed linear modeling was employed to analyze longitudinal changes while controlling for confounding variables such as age, BMI, and smoking status.
Baseline Epigenetic Profiles
A key finding was the significant difference in baseline methylation levels between the groups. Patients in the ECT group, who typically present with more chronic and severe depressive symptoms, exhibited the highest levels of POMC methylation (0.252) compared to both UDCs (0.156) and HCs (0.162) ($p < 0.001$). This elevation suggests that prolonged or severe depression may leave an "epigenetic scar" on the POMC gene, potentially contributing to the chronification of the disorder.
Similarly, NR3C1 methylation at baseline was significantly higher in the ECT group (0.031) compared to healthy controls (0.024) and unmedicated depressed patients (0.014) ($p < 0.001$).
Treatment Response and Temporal Dynamics
The study identified NR3C1 methylation as a potential predictor of clinical outcome. Responders to ECT demonstrated significantly lower baseline NR3C1 methylation levels compared to non-responders ($p < 0.001$). This suggests that epigenetic screening prior to treatment could help clinicians estimate the likelihood of ECT success for individual patients.
Furthermore, the research captured the acute molecular effects of ECT. Methylation levels for both NR3C1 and POMC decreased significantly immediately following the first ECT session (both $p \leq 0.001$). This rapid "epigenetic reset" occurs before significant clinical improvement is typically observed, indicating that ECT exerts immediate effects on the molecular regulation of the stress response.
Discussion and Limitations
These results highlight the potential of blood-based epigenetic biomarkers in psychiatric precision medicine. However, several limitations must be considered. The sample size (n=70) is relatively small, necessitating larger replication studies. Additionally, while peripheral blood samples are clinically practical, they may not fully represent the epigenetic state of brain tissue. The age difference between the ECT group and controls, though statistically managed, remains a potential confounder given the known impact of aging on DNA methylation.
Future research should utilize Next-Generation Sequencing (NGS) to explore a wider array of epigenetic marks and investigate the correlation between these methylation changes and mRNA or protein expression to further elucidate the biological mechanisms of depression and its treatment.
Summary updated